HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 2,400.00
+45.00 (1.91%)
Aug 12, 2026, 3:30 PM KST
HLB Therapeutics Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 217,998 | 251,873 | 934,494 | 331,363 | 365,136 | 378,914 | |
Market Cap Growth | -26.04% | -73.05% | 182.02% | -9.25% | -3.64% | -51.22% |
Enterprise Value | 263,757 | 270,609 | 946,064 | 315,400 | 359,859 | 380,861 |
Last Close Price | 2355.00 | 2857.14 | 10621.32 | 3977.32 | 4907.60 | 5990.56 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 103.69 | 103.69 | 103.69 | 103.69 | 103.69 |
PS Ratio | 3.23 | 3.62 | 17.01 | 6.30 | 8.61 | 8.69 |
PB Ratio | 1.24 | 1.45 | 5.14 | 1.93 | 2.85 | 2.91 |
P/TBV Ratio | 4.54 | 1.82 | 6.37 | 2.21 | 3.28 | 3.31 |
P/FCF Ratio | - | - | 1435.95 | 109.54 | - | - |
P/OCF Ratio | - | - | 725.68 | 99.60 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.90 | 3.89 | 17.22 | 6.00 | 8.49 | 8.74 |
EV/EBITDA Ratio | - | 260.12 | 2022.13 | - | - | - |
EV/FCF Ratio | - | - | 1453.73 | 104.26 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.23 | 0.13 | 0.06 | 0.41 | 0.39 |
Debt / EBITDA Ratio | - | 38.98 | 49.91 | - | - | - |
Debt / FCF Ratio | - | - | 35.88 | 3.31 | - | - |
Net Debt / Equity Ratio | 0.12 | -0.03 | -0.08 | -0.13 | -0.09 | -0.38 |
Net Debt / EBITDA Ratio | -11.62 | -5.24 | -30.82 | 57.35 | 2.03 | 5.27 |
Net Debt / FCF Ratio | -2.68 | 0.58 | -22.16 | -7.38 | 0.97 | 4.09 |
Asset Turnover | 0.30 | 0.31 | 0.26 | 0.27 | 0.23 | 0.28 |
Inventory Turnover | 9.66 | 9.44 | 8.40 | 7.70 | 7.66 | 13.82 |
Quick Ratio | 0.94 | 2.31 | 1.46 | 1.58 | 1.24 | 1.91 |
Current Ratio | 1.34 | 2.84 | 1.70 | 1.86 | 1.37 | 2.00 |
Return on Equity (ROE) | -5.41% | -5.44% | -12.97% | -1.98% | -8.97% | -15.42% |
Return on Assets (ROA) | -1.44% | -1.00% | -2.27% | -2.85% | -2.49% | -4.45% |
Return on Capital Employed (ROCE) | -2.70% | -1.80% | -4.10% | -5.10% | -5.80% | -8.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -4.17% | -3.66% | -2.44% | -0.69% | -3.11% | -4.54% |
FCF Yield | -3.60% | -3.76% | 0.07% | 0.91% | -3.34% | -3.19% |
Buyback Yield / Dilution | -3.55% | -4.35% | -3.23% | -14.46% | -10.86% | -7.26% |